Kornimate/medical-research-clean huggingface dataset:
defibrillation in accidental hypothermia

Conditions: Hypothermia, Accidental; Defibrillation

Summary: hypothermia (core temperature ≤35°c) is a frequent and life-threatening complication after mountain accidents, near-drowning, and intoxications, and can provoke arrhythmia, reduced cardiac contractility, and cardiac arrest. the hypothermic heart may be insensitive to defibrillation with a core temperature \ 30°c if vf persists after 3 shocks. epinephrine should be withheld if core temperature is \<30°c. advanced life support (als) guidelines of the american heart association (aha) state that it may be reasonable to perform further defibrillation attempts according to the standard algorithm and to consider administration of a vasopressor during cardiac arrest (table 1). this discrepancy between erc and aha guidelines can be explained by the different interpretations of mainly animal data, which show that vasopressors increase the chances of successful defibrillation \<30°c, defined as return of spontaneous circulation (rosc) for at least 30 seconds. the guidelines of the wilderness and environmental medicine society (wms) state that a single shock at a maximum power can be given for patients with a temperature \<30°c. the aim of this study is to evaluate clinical course of hypothermic patients(\<30°c) undergoing defibrillation. the primary aim is to evaluate the success ratio of defibrillation, defined as rosc for at least 30 seconds. secondary aims are the recurrence rate of ventricular fibrillation, the number of defibrillation attempts per patient, the presence of cardiac dysfunction after defibrillation and the cerebral performance category (cpc) score at the end of hospitalization.


Eligibility criteria:
inclusion criteria: - patients of the international hypothermia registry with a defibrillation while having a body core temperature equal or less than 30°c exclusion criteria: * patients of the international hypothermia registry with a body core temperature \>30°c * patients who refused to participate
neopterin effects on ischemic stroke

Conditions: Stroke

Summary: ischemic stroke accounts for the majority of stroke cases and constitutes a major cause of death and disability in industrial world. inflammation has been reported to constitute a major component of ischemic stroke pathology. the brain responds to ischemic injury with an acute andprolonged inflammatory process. few studies have investigated the relationship between acute biomarkers of inflammation and functional outcome following stroke

this case -control observational prospective study will be conducted on 100 patients with first -ever acute onset ischemic stroke within 24-48 hours. their ages ranged-years old (mean age ±years). all participants will be subjected to thorough history taking, full clinical and neurological examination. complete neurological examination where the following clinical and demographical data will be taken; age sex, stroke etiology, presence of stroke risk factors (as smoking history , hyperlipidemia, diabetes mellitus , history of hypertension, history of transient ischemic attacks, history of myocardial infarction or any cardiac problems). stroke subtype will be classified according to the criteria of trial of org 10172 in acute stroke treatment (toast) classification. the clinical stroke syndrome will be determined by applying the criteria of the oxfordshire community stroke project (ocsp). stroke severity will be assessed by scandinavian stroke scale (sss) and modified rankin scale (mrs) will be measured at the time of admission. brain imaging (either ct scan and /or mri) will be performed after admission. electrocardiography (ecg), echocardiography (echo), carotid and vertibrobasilar duplex will be done for all patients. blood samples will be drawn for assessment of complete blood picture (cbc), random blood glucose levels, renal function tests (rft), liver function tests (lft), thyroid function tests (tft), lipid profile, soluble cd40 ligand and neopetrin by using standard laboratory methods on the first day of admission.

Eligibility criteria:
inclusion criteria: * onset is within one week * confirmed stroke by brain cat and / or mri scan infarction * exclusion criteria: * cognitive and mental changes * recurrent stroke * hepatic and renal impairment * endocrinal diseases * steroid therapy * previous fractures * brain neoplasm, * autoimmune diseases * history of acute and chronic inflammatory diseases * malignancy, * trauma * surgery * acute vascular diseases that occurred within four weeks prior the onset of stroke history myocardial infarction ˂3 months.

Keywords: ischemic stroke soluble cd40 ligand neopetrin stroke risk factors functional outcome
intragastric and peritoneal microdialysis in infants with necrotizing enterocolitis (nec)

Conditions: Necrotizing Enterocolitis

Summary: nec is a serious inflammatory bowel disease, which almost only strikes infants with low birth weight and low gestational age. the morbidity and mortality rates are high, and early diagnosis and treatment is mandatory. the primary aim of the present study is to investigate the clinical use of intragastric microdialysis and whether it is able to select patients, who may benefit from either medical or surgical therapy. the aim of intraperitoneal microdialysis is to evaluate whether changes in intraperitoneal microdialysis reflect the clinical outcome after laparotomy.

neonates who are hospitalized because of suspicion of nec are subjected to intragastric microdialysis during the observation period. the catheter is placed in the stomach via the naso-oesophageal route. if surgery is necessary a microdialysis catheter is placed in the peritoneal cavity prior to wound closure. samples are collected every 4-hour. samples will be analyzed continuously but the results will not be included in the clinical evaluation of the patient. a total of 20 patients will be included in this pilot study. the results of the intragastric and peritoneal microdialysis will be compared with the clinical course, s-lactate, radiological and pathological findings in each patient.

Eligibility criteria:
inclusion criteria: * neonates who are hospitalized because of suspicion of nec. * neonates who has surgery because of nec. exclusion criteria: * non-acceptance from the child's parents or custody holder

Keywords: necrotizing enterocolitis intragastric microdialysis peritoneal microdialysis infants
the effect of a laryngeal mask airway on optic nerve sheath diameter

Conditions: Intracranial Pressure Increase

Summary: the goal of this observational trial is to study the effect of a laryngeal airway mask on the optic nerve sheath diameter, as a surrogate for intracranial pressure. the optic nerve sheath diameter of participants will be measured under general anesthesia, before, during and after insertion of a laryngeal airway mask.


Eligibility criteria:
inclusion criteria: * in order to be eligible to participate in this study, a subject must meet all of the following criteria: aged 18 years or older, asa i or asa ii, scheduled for elective surgery under general anesthesia, with a planned duration of \> 30 minutes, that can be routinely performed with a lma. exclusion criteria: * scheduled for head or neck surgery * scheduled for neurosurgery * scheduled for laparoscopic or thorascoscopic procedures * scheduled for procedures that require trendelenburg or anti-trendelenburg positioning * neurological disorders * glaucoma * history of bilateral eye related trauma * intellectual disability

Keywords: laryngeal airway mask optic nerve sheath diameter intracranial pressure
evaluation of safety and efficacy of remifentanil in pediatric population

Conditions: Infant, Preterm

Summary: the purpose of this study is to evaluate safety and efficacy of continuous infusion of remifentanil in preterm infant with mechanical ventilator for control of procedural pain using two different dosage of remifentanil.


Eligibility criteria:
inclusion criteria: * preterm infants mechanically ventilated * requiring peripherally induced central catheterization * with informed consent of their parents exclusion criteria: * major congenital anomalies * cardiopulmonary instability * use of sedative, antiepileptic drugs or anesthetic drugs * grade iii or iv intraventricular hemorrhage
safety and efficacy of viscosupplementation of hyaluronic acid with addition of lecithin in patients with mild or moderate osteoarthrosis of the knee joint.

Conditions: Osteoarthritis, Knee

Summary: the main objective of this prospective, open-label clinical trial is to assess the effectiveness and safety of intra-articular liposomal gel therapy for knee oa symptoms.


Eligibility criteria:
inclusion criteria: * age between 38 and 70 years, * oa diagnosed by the american college of rheumatology (acr) criteria, * oa diagnosed by radiographic imaging (grade ii - iii according to the kellgren-lawrence scale), * pain in the knee joint for at least 3 months, * screening pain intensity in the target knee measured on vas scale was required to be 4 for symptomatic knee and 2 for the contralateral knee. exclusion criteria: * previous injections of hyaluronic acid or platelet-rich plasma within 6 months or corticosteroid injections within 3 months before the enrollment, * present joint infection, * previous knee arthroscopy up to 1 year prior to examination, * peripheral inflammatory and autoimmune diseases that progress with joint involvement (rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematosus etc.), * total arthroplasty and osteotomy, * ankylosis of the study joint, * dermatitis or dermatological disease at the intended injection site, * known hypersensitivity to the components of the preparation, * coexistence of the degenerative changes in other limb joints (hip, foot), * cancer, * oral corticosteroid therapy, * use of medicines that affect blood clotting (heparins, oral anticoagulants, thrombolytic drugs), * pregnancy or breast-feeding. * history of injury to the knee, a broken bone or dislocation of a joint, other musculoskeletal diseases that affect the study joint, neoplastic disease. * participation in other clinical trials.
effect of triclosan-coated suture on superficial ssi

Conditions: Surgical Site Infection

Summary: the abdominal closure with triclosan coated suture will reduce superficial surgical site infection.


Eligibility criteria:
inclusion criteria: * fecal peritonitis exclusion criteria: * perioperative mortality

Keywords: triclosan coated suture surgical site infection fecal peritonitis superficial incisional
a trial of a positive psychology intervention for older adults (reset) during the covid-19 pandemic

Conditions: Depressive Symptoms; Anxiety; Chronic Pain; Fatigue; Loneliness; Stress, Psychological

Summary: the heightened vulnerability to covid-19 of african american older adults in detroit, michigan and other marginalized communities is linked to systemic racism experienced over the life course. structural inequities also magnify the pandemic's impact on older adults' physical and psychosocial functioning. many older adults in detroit, burdened by poor health even before the pandemic, face a downward spiral of increased distress, reduced physical and social activity, and physical deconditioning. reset (re-engaging in self-care, enjoying today) is a self-management and resilience-building intervention led by community health workers (chws) at the detroit health department (dhd). the central hypothesis of this study is that reset, with components that include group telephone calls, a podcast series, and activity trackers, will improve psychosocial and physical functioning at 2 and 8 months. specific aims are: 1) with input from a community advisory board, modify reset for group delivery and refine content after testing in a mini-pilot (n=10). 2) conduct a randomized, controlled trial to assess the impact of reset (compared to a one-time /telephone wellness check) on promis-29 psychosocial score (a weighted combination of distress, fatigue, pain, social participation and sleep) among 456 primarily african american older adults age 50 and over who are at elevated risk of poor functioning. 3) collect qualitative (interview) data from participants and other stakeholders, and use this data to better understand trial results, as well as to assess community impact and inform a dissemination toolkit.


Eligibility criteria:
inclusion criteria: * any elevated physical or psychosocial symptoms as follows: depression: score ≥3 on the patient health questionnaire-2 (phq-2); anxiety: score \> 3 on the gad-2 anxiety screening scale; fatigue: rating \>=4 on a 0 to 10 scale (0 = fatigued at all and 10 = extremely fatigued); loneliness, as indicated by a score \>=6 on 3-item ucla loneliness scale; perceived stress, as indicated by a mean score \>3 on the perceived stress scale-4; chronic pain: self-reported pain in muscles or joints for \>3 months, \>4 (0-10 scale) mean pain intensity over last month, and \>=1 day in past month when pain made it difficult to do usual activities. * have a cell or landline phone. * able to converse comfortably in english. exclusion criteria: * serious acute illness or hospitalization in last month. * planned major surgery in next three months that would interfere with program participation (e.g., knee or hip replacement). * severe cognitive impairment or dementia. * any other diseases or conditions that would impair cooperation with the study team or ability to complete study procedures, as determined by the clinicians on the investigative team. this would include but not be limited to severe psychiatric disorders, active suicidal ideations or history of suicide attempts, and an uncontrolled drug and/or alcohol addiction).
types of starch and their effect on blood glucose, appetite and food intake

Conditions: Obesity Prevention; Diabetes Prevention

Summary: the investigators hypothesize that different types of starch vary in their effects on appetite, blood sugar and food intake. in this study, subjects consumed five soups containing 50 g of whole grain, high amylose corn, regular corn or maltodextrin starches or no added starch at one week intervals. the investigators measured food intake at 120 minutes, appetite and blood sugar.


Eligibility criteria:
inclusion criteria: * healthy males with a bmi of 20-24.9 kg/m2 exclusion criteria: * females * smokers * breakfast skippers * individuals with diabetes or other metabolic diseases

Keywords: starch carbohydrates blood glucose food intake satiety appetite
long-term effects of the addition of diathermy by emission of radiofrequency to therapeutic exercise in patellofemoral pain syndrome patients

Conditions: Patellofemoral Pain Syndrome; Patellofemoral Pain; Patello Femoral Syndrome

Summary: introduction: the management of patellofemoral pain (pfp) is focused on therapeutic exercise (te) to improve muscle strength and motor control. recent studies suggest that the addition of radiofrequency diathermy (rfd) obtain greater short-term improvements in knee pain than te alone. as there is no follow up data, the aim of this research is to assess the long-term effects of adding rfd to te on pain, function and quality of life on pfp patients. methods: a single-blind randomized controlled trial will be conducted. participants diagnosed of pfp will be allocated in either a te group or a rfd+te one. sociodemographic data, knee pain, and lower limb function will be collected. each group will performed 20 min of daily knee and hip supervised te along three weeks with the addition of ten sessions of rfd for the rfd+te group.


Eligibility criteria:
inclusion criteria: * subjects between 30 and 50 years old without radiological findings of osteoarthritis. * subjects referring during the last month almost three points of pain in the anterior surface of knee measured with visual analogue scale. exclusion criteria: * subjects with contraindications for the treatment with radiofrequency diathermy (tumors, use of pacemakers or any other implanted electronic device, thrombophlebitis or deep venous thrombosis, pregnancy, fever, active tuberculosis, infections and rheumatoid arthritis). * subjects who have received corticoid or hyaluronic acid or platelet-rich plasma injections treatment in the knee.

Keywords: knee pain electrophysical agents
med-alert bracelet in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: this is a pilot observational study to evaluate subjects with chronic kidney disease acceptance of an alert device linked to an informational website intended to increase recognition of chronic kidney disease, and to guide patients and providers to the safe delivery of care required for this disease. primary device was a bracelet with the alternative of a key fob with same information supplied when requested. patients usage of the device was evaluated by survey with likert scale as to whether the device is 0 = not useful, 1 = somewhat useful, 2 = extremely useful

no need for more extensive description

Eligibility criteria:
inclusion criteria: * persons with chronic kidney disease defined as estimated glomerular filtration rate of \< 60 ml/min/1.73m2. exclusion criteria: * persons expected to be on dialysis within 6 months. * less than 18 years of age

Keywords: patient safety chronic kidney disease med-alert
onabotulinumtoxina (botox®) treatment for urinary incontinence in patients with overactive bladder

Conditions: Overactive Bladder

Summary: this is a study to evaluate the efficacy and safety of onabotulinumtoxina (botox®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (oab) not properly managed with an anticholinergic.


Eligibility criteria:
inclusion criteria: -patients with symptoms of overactive bladder (oab) (frequency and urgency) with urinary incontinence for at least 6 months prior to screening. exclusion criteria: * symptoms of oab due to a neurological reason * use of anticholinergics or other medications or therapies to treat symptoms of oab within 7 days of screening * use of clean intermittent catheterization (cic) or indwelling catheter to manage urinary incontinence * use of botulinum toxin therapy of any serotype for any urological condition * use of botulinum toxin therapy of any serotype for any non-urological condition in the 12 weeks prior to screening * history of any pelvic or urological abnormalities, bladder surgery or disease, other than oab, that may affect bladder function * diagnosis of myasthenia gravis, eaton-lambert syndrome, or amyotrophic lateral sclerosis.
the diagnostic ability of white light endoscopy and magnifying endoscopy with optical enhancement system

Conditions: Early Gastric Cancer

Summary: the purpose of this study is to valuation of the diagnostic ability of white light imaging and magnifying endoscopy with optical enhancement system in early gastric cancer and intraepithelial neoplasia.

stomach cancer is the second most common cause of cancer death. endoscopic identification and treatment of gastric intestinal metaplasia (gim) and early gastric cancer (egc) is essential to improve patients' 5-year survival rates. conventional endoscopy with white light imaging (wli) is widely used for endoscopic evaluation of egcs. however, conventional endoscopic visualization of egcs has a high rate of interobserver variability and correlates poorly with the histological findings. for this reason, diagnosis has been based mostly on repeated endoscopy with multiple biopsy samples. it has been reported that optical enhancement (oe) system is useful for discriminating cancerous lesions from non-cancerous lesions. the oe system is the newly developed image-enhanced endoscopic technology, which combines high definition white light endoscopy (wle) and optical filters that limit the spectral characteristics of the illumination light. the optical filters can achieve higher overall transmittance by connecting the peaks of the hemoglobin absorption spectrum creating a continuous wavelength spectrum. magnifying endoscopy is useful for observing the mucosal structures and microvessels. the vs theory proposed by yao k is widely used in magnifying endoscopy with optical enhancement system (me-oe). based on technical considerations, it is conceivable that me-oe imaging techniques might have a distinct advantage over wle in the diagnosis of endoscopic lesions. however, few reports have objectively proved that me-oe is superior to wle in the detection rate and diagnostic efficiency of egcs.

Eligibility criteria:
inclusion criteria: * patients aged 18-80 years with h. pylori infection or histologically verified gastric lesions (chronic atrophic gastritis, intestinal metaplasia, gin or egc) * or patients aged 40-80 years from a region with high incidence of gastric cancer * or patients aged 40-80 years with first-degree relative of patients with gastric cancer * or patients aged 40-80 years with high-risk factors for gastric cancer (high salt or pickle diet or smoking or heavy drinking) exclusion criteria: * a history of gastrectomy * active gastrointestinal bleeding or advanced gastric carcinoma * coagulopathy or severe underlying diseases * pregnancy or lactation * absence of informed consent

Keywords: early gastric cancer, optical enhancement system
a biomarker study of secukinumab in rheumatoid arthritis (ra) patients

Conditions: Rheumatoid Arthritis

Summary: this study aims to confirm if patients with a specific biomarker might have a better response to secukinumab treatment. to meet this purpose, exploratory biomarker studies will be done. the goals of these exploratory studies are to (1) find biomarkers that will identify persons with rheumatoid arthritis who will have the best possible response to secukinumab and (2) to identify persons who will have fewer side effects in order to maximize their benefit from secukinumab.


Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis * patients must be either dmard naive or have failed at least one dmard agent (e.g. mtx, leflunamide or sulfasalazine) * patients are allowed up to 3 dmards at study entry (e.g. mtx, sulfasalazine or hydroxychloroquine) as long as their dose was stable for 4 weeks prior to initiating study treatment * disease activity at screening defined by ≥6 out of 28 tender joints and ≥6 out of 28 swollen joints and hscrp \>10mg/l exclusion criteria: * patients with severe rheumatoid arthritis (functional status class iv according to the acr 1991 revised criteria) * previous exposure to secukinumab or any other biologic, including tnf inhibitors. * use of high potency opioid analgesics * pregnant or nursing (lactating) women * use of any investigational drug other than ra therapy and/or devices at the time of randomization or within 30 days or 5 half-lives of randomization, whichever is longer. other protocol-defined inclusion/exclusion criteria may apply

Keywords: rheumatoid arthritis igg1k monoclonal antibody interleukin-17a neutralizing